US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

11.03

-0.3900-3.42%

Post-market: 11.100.0700+0.63%19:46 EDT

Volume:2.19M

Turnover:24.07M

Market Cap:1.43B

PE:-4.89

High:11.76

Open:11.39

Low:10.57

Close:11.42

52wk High:28.23

52wk Low:10.57

Shares:129.54M

Float Shares:44.92M

Volume Ratio:1.37

T/O Rate:4.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.28

PE(LYR):0.00

Loading ...

Overview Company News Filings

Evercore ISI Kailera Therapeutics Initiates at Outperform

MT Newswires Live

Kailera Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $36

THOMSON REUTERS

Kailera Therapeutics initiated with a Buy at TD Cowen

Analysts Offer Insights on NA Companies: Douglas AG (OtherDOUDF) and Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics initiated with an Outperform at William Blair

Biotech firm Odyssey targets $810 million valuation in US IPO

Kailera Therapeutics IPO Debut And Index Inclusion Spur Early Assessment

Simply Wall St.

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

Benzinga_recent_news

Major Investor Makes Bold Move Into Kailera Therapeutics

RTW Investments buys 500,000 Kailera Therapeutics shares for $8 million

Stock Track | Kailera Therapeutics Soars 5.24% in Pre-Market on Insider Buying Spree

Massive Insider Buying Spree Signals Surging Confidence in Kailera Therapeutics

Kailera director Adam Koppel reports acquiring 1,562,500 shares for $25 million

Bain Capital Life Sciences Investors acquires 1,562,500 Kailera Therapeutics shares for $25 million

Kailera director Andrew Kaplan acquires 8,398,438 shares valued at $134.4 million

Kailera Therapeutics Closes Initial Public Offering

MT Newswires Live

Stock Track | Kailera Therapeutics Plummets 5.35% Intraday on Corporate Governance Changes

Kailera Therapeutics adopts amended bylaws setting new stockholder proposal, director nomination rules

Kailera Therapeutics closes IPO, raises USD 718.8 million at USD 16 share

Kailera Stock (KLRA) Rockets 68% after IPO as It Chases $76B Obesity Opportunity

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/KLRA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":11.03,"timestamp":1790884800000,"preClose":11.42,"halted":0,"volume":2187244,"hourTrading":{"tag":"盘后","latestPrice":11.1,"preClose":11.03,"latestTime":"19:46 EDT","volume":105450,"amount":1163180.33,"timestamp":1790898365861,"change":0.07,"changeRate":0.006346,"amplitude":0.006346},"delay":0,"changeRate":-0.03415061295971984,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Not Yet Opened","change":-0.39,"latestTime":"10-01 16:00:00 EDT","open":11.39,"high":11.76,"low":10.565,"amount":24071768.5231,"amplitude":0.104641,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790928000000},"marketStatusCode":0,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":11.42,"preHourTrading":{"tag":"盘前","latestPrice":11.42,"preClose":11.42,"latestTime":"08:19 EDT","volume":16,"amount":182.72,"timestamp":1790857185140,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.1,"preClose":11.03,"latestTime":"19:46 EDT","volume":105450,"amount":1163180.33,"timestamp":1790898365861,"change":0.07,"changeRate":0.006346,"amplitude":0.006346},"volumeRatio":1.370069},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":1.370069,"shares":129537300,"dividePrice":0,"high":11.76,"amplitude":0.104641,"preClose":11.42,"low":10.565,"week52Low":10.565,"pbRate":"1.28","week52High":28.2271,"institutionHeld":0,"latestPrice":11.03,"eps":-2.254252,"divideRate":0,"volume":2187244,"delay":0,"ttmEps":-2.254252,"open":11.39,"prevYearClose":16,"prevWeekClose":11.215,"prevMonthClose":11.42,"prevQuarterClose":11.42,"fiveDayClose":11.98,"twentyDayClose":15.85,"sixtyDayClose":21.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"date":"2026-11-04","symbol":"KLRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1793826000000,"name":null,"time":"Post-Mkt","dateTimestamp":1793768400000,"actualEps":null},{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-09-30","current":-4.892976,"percent":1,"low":-21.871461,"twenty":-18.817283,"median":-12.75669,"eighty":-7.562182,"high":-4.876108,"avg":-13.331086,"sd":5.292403,"marketCap":1424783999},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-28","current":-8.221499,"twenty":-19.532674,"median":-16.131833,"eighty":-11.014222,"marketCap":2402297316},{"date":"2026-09-04","current":-6.983615,"twenty":-19.497291,"median":-13.667441,"eighty":-10.594351,"marketCap":2040591460},{"date":"2026-09-11","current":-6.615356,"twenty":-19.448642,"median":-13.506901,"eighty":-10.353542,"marketCap":1932987209},{"date":"2026-09-18","current":-5.732421,"twenty":-19.325153,"median":-12.9728,"eighty":-8.138973,"marketCap":1674996293},{"date":"2026-09-25","current":-5.315357,"twenty":-18.99469,"median":-12.812261,"eighty":-7.882523,"marketCap":1553131238},{"date":"2026-09-30","current":-4.876108,"twenty":-18.817283,"median":-12.75669,"eighty":-7.562182,"marketCap":1424783999}],"updateTime":1790908571311},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634139662","title":"Evercore ISI Kailera Therapeutics Initiates at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2634139662","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634139662?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:13","pubTimestamp":1778584422,"startTime":"0","endTime":"0","summary":"Evercore ISI Kailera Therapeutics Initiates at Outperform","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634297885","title":"Kailera Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2634297885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634297885?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:04","pubTimestamp":1778580293,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292860","title":"Kailera Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634292860?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:37","pubTimestamp":1778578626,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Kailera Therapeutics (KLRA) with a Buy rating and $57 price target The company’s lead asset ribupatide is “different...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","TD","BK4207","BK4585","COWN","BK4139","BK4127","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291061","title":"Analysts Offer Insights on NA Companies: Douglas AG (OtherDOUDF) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634291061?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:21","pubTimestamp":1778577672,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Douglas AG (DOUDF) and Kailera Therapeutics, Inc. (KLRA) wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-douglas-ag-otherdoudf-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-douglas-ag-otherdoudf-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4200","BK4141","DOUDF","NA","BK4139","BK4210","AG","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634294839","title":"Kailera Therapeutics initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2634294839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634294839?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:15","pubTimestamp":1778577310,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating. Kailera is advancing a pipeline of GL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932017","title":"Biotech firm Odyssey targets $810 million valuation in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932017","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932017?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:48","pubTimestamp":1777891715,"startTime":"0","endTime":"0","summary":"UPDATE 2-Biotech firm Odyssey targets $810 million valuation in US IPOAdds details throughout. May 4  - Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States, as investors warm up to drug developers. The Boston-based company is seeking to raise up to $238.3 million by offering 13.2 million shares priced between $16 and $18 apiece. The U.S. IPO market has made a strong comeback in recent weeks, setting the stage for a pickup in listings in coming months.Last month, weight-loss drug developer Kailera Therapeutics KLRA.O, Alamar Biosciences ALMR.O and nuclear reactor maker X-Energy XE.O made stellar market debuts.April marked the biggest month for new filings in more than four years, according to Renaissance Capital, a provider of IPO-focused research and ETFs. This despite a volatile first quarter amid a sell-off in tech stocks, private credit strains and the Middle East confli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL4N41H0NW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310799852.SGD","LU2420271590.USD","DIPS","SGXZ81514606.USD","NVDO","NVDW","NVD","LU0158827948.USD","SNVD.UK","LU1989772923.USD","XE","NVDG","LU0265550359.USD","LU2236285917.USD","LU0072462426.USD","NVDU","SGXZ23171101.USD","NVDS.UK","LU0345768153.USD","LU0345768740.USD","NVII","NVDA","NVD3.UK","LU1934455277.USD","NVDL","LU1153585028.USD","NVDX","LU2756315664.SGD","NVDD","IE000YTNTUN2.SGD","KLRA","NVDQ","3NVD.UK","ANV","LU0061474705.USD","NVDB","IE00B3SWFQ91.USD","NVD2.UK","2NVD.UK","NVDS","BK4533","BK4532","LU1803068979.SGD","NVDY","LU2552382132.HKD","LU1267930490.SGD","NVIW.SI","LU0724617625.USD","LU0965509283.SGD","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852200","title":"Kailera Therapeutics IPO Debut And Index Inclusion Spur Early Assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852200","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629852200?lang=en_us&edition=fundamental","pubTime":"2026-04-24 02:12","pubTimestamp":1776967958,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics completed its IPO and began trading on the Nasdaq Global Select Market under the ticker NasdaqGS:KLRA.\nThe company has been added to the NASDAQ Composite Index, broadening its exposure to index-tracking investors.\nShares most recently closed at $24.30, with a year-to-date return reflecting a 6.5% decline.\n\n\nKailera Therapeutics, now trading as NasdaqGS:KLRA, has moved from private funding into the public markets with its Nasdaq Global Select Market listing. With a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klra/kailera-therapeutics/news/kailera-therapeutics-ipo-debut-and-index-inclusion-spur-earl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klra/kailera-therapeutics/news/kailera-therapeutics-ipo-debut-and-index-inclusion-spur-earl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain","QID","QQQY","QQQ","NVIW.SI","MNQmain","IYW","QDTE","NDX","SPCX","QQQA","QLD","KLRA","SQQQ","TQQY","QQQM","GPIQ","PSQ","QQQJ","IPOS","FTEC","QYLG",".IXIC","ONEQ","TQQQ","JEPQ","QQQE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629599348","title":"Kailera Therapeutics' Strong IPO Validates \"NewCo\" Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2629599348","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629599348?lang=en_us&edition=fundamental","pubTime":"2026-04-24 00:08","pubTimestamp":1776960480,"startTime":"0","endTime":"0","summary":"A company set up to develop Hengrui Pharma's weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the \"NewCo\" business model. When Chinese drugmakers began spinning off promising pipelines into standalone companies, they faced market concern and skepticism. The strategy was considered an unproven and potentially risky way to monetize their clinical assets.But the attitude towards these so-called NewCos – corporate vehicles housing specific drugs under development – has brightened this year after one of the Chinese spin-offs was bought out by a multinational, delivering a big payoff for the original developer.The newly listed firm was set up as a corporate wrapper for Hengrui Pharma's GLP-1 assets, with shareholders including Bain Capital Life Sciences, Atlas Venture, RTW Investments and Lyra Capital, along with other specialized investment institutions. The Kailera share price surged about 63% on its first U.S. trading day, offering a windfall opp","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/23/-23-4-2026-101430-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/23/-23-4-2026-101430-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/04/52006951/kailera-therapeutics-strong-ipo-validates-newco-strategy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/04/52006951/kailera-therapeutics-strong-ipo-validates-newco-strategy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IPOS","KLRA","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629070227","title":"Major Investor Makes Bold Move Into Kailera Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2629070227","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629070227?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:01","pubTimestamp":1776909701,"startTime":"0","endTime":"0","summary":"New insider activity at Kailera Therapeutics, Inc. ( ($KLRA) ) has taken place on April 22, 2026. Significant shareholder RTW INVESTMENTS, LP has i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-into-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-into-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629020224","title":"RTW Investments buys 500,000 Kailera Therapeutics shares for $8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629020224","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629020224?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:20","pubTimestamp":1776889245,"startTime":"0","endTime":"0","summary":"RTW Investments reported a larger stake in Kailera Therapeutics, taking beneficial ownership to 10,776,820 common shares.Filing showed purchase of 500,000 shares at USD 16.Roderick Wong, managing partner at RTW Investments, was listed as a reporting beneficial owner.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6Kd310:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RTW Investments buys 500,000 Kailera Therapeutics shares for $8 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160047386","title":"Stock Track | Kailera Therapeutics Soars 5.24% in Pre-Market on Insider Buying Spree","url":"https://stock-news.laohu8.com/highlight/detail?id=1160047386","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160047386?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:44","pubTimestamp":1776775466,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA) experienced a significant pre-market surge of 5.24% on Tuesday, indicating heightened investor activity before the opening bell.The sharp upward movement appears to be...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629705962","title":"Massive Insider Buying Spree Signals Surging Confidence in Kailera Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2629705962","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629705962?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:03","pubTimestamp":1776736981,"startTime":"0","endTime":"0","summary":"New insider activity at Kailera Therapeutics, Inc. ( ($KLRA) ) has taken place on April 20, 2026. Kailera Therapeutics, Inc. has seen a major wave ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/massive-insider-buying-spree-signals-surging-confidence-in-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/massive-insider-buying-spree-signals-surging-confidence-in-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SHAP.U","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629717667","title":"Kailera director Adam Koppel reports acquiring 1,562,500 shares for $25 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629717667","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629717667?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:09","pubTimestamp":1776722961,"startTime":"0","endTime":"0","summary":"Adam Koppel, director, reported an increase in indirect ownership of Kailera Therapeutics common stock to 22,583,268 shares.Filing showed acquisition of 1,562,500 shares at USD 16 per share.Report also reflected conversion into common stock of 16,875,000 shares of Series A-1 Preferred Stock.Conversion into common stock of 4,145,768 shares of Series B Preferred Stock was also reported.Koppel reported receipt of a stock option for 38,300 shares with an exercise price of USD 16.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL2sh4yf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629714107","title":"Bain Capital Life Sciences Investors acquires 1,562,500 Kailera Therapeutics shares for $25 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629714107","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629714107?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:02","pubTimestamp":1776722549,"startTime":"0","endTime":"0","summary":"Bain Capital Life Sciences Investors, a 10% owner, reported a sharp increase in its stake in Kailera Therapeutics.Holdings rose to 22,583,268 shares of common stock held indirectly.Filing showed 1,562,500 shares were purchased at USD 16 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL4ddHgv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629777146","title":"Kailera director Andrew Kaplan acquires 8,398,438 shares valued at $134.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629777146","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629777146?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:00","pubTimestamp":1776722459,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics director Andrew T. Kaplan reported an increase in beneficial ownership to 26,255,581 shares of common stock held indirectly.Filing also showed acquisition of 8,398,438 shares at USD 16 per share.Kaplan also received stock options for 38,300 shares with an exercise price of USD 16.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL9J7mN5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kailera director Andrew Kaplan acquires 8,398,438 shares valued at $134.4 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629799417","title":"Kailera Therapeutics Closes Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629799417","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629799417?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:05","pubTimestamp":1776719159,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics  said Monday it has closed its initial public offering of about 44.9 million shares, including the exercise in full by the underwriters of an option to buy nearly 5.9 million additional shares, at $16 per share, for gross proceeds of $718.8 million.All of the shares were offered by the company, according to a statement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPOS","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109550352","title":"Stock Track | Kailera Therapeutics Plummets 5.35% Intraday on Corporate Governance Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1109550352","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109550352?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:22","pubTimestamp":1776716549,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics' stock experienced a significant decline of 5.35% during Monday's intraday trading session.The sharp drop followed the company's announcement that it has adopted amended and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629768777","title":"Kailera Therapeutics adopts amended bylaws setting new stockholder proposal, director nomination rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2629768777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629768777?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:19","pubTimestamp":1776716378,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics implemented amended and restated bylaws on April 20, 2026 in connection with IPO closing.Bylaws set advance-notice procedures for stockholder proposals at meetings.Changes align bylaws with corporate governance provisions in restated charter, including classified board structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL331r0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629377528","title":"Kailera Therapeutics closes IPO, raises USD 718.8 million at USD 16 share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629377528","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629377528?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:10","pubTimestamp":1776715839,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics closed initial public offering of 44,921,875 shares of common stock at USD 16 per share.Gross proceeds totaled USD 718.8 million before underwriting discounts, commissions, and offering expenses.Underwriters exercised option in full to purchase 5,859,375 additional shares.Common stock began trading on Nasdaq Global Select Market under ticker KLRA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL7r1fpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2V16.EUR","KLRA","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","BK4112","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628478627","title":"Kailera Stock (KLRA) Rockets 68% after IPO as It Chases $76B Obesity Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2628478627","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628478627?lang=en_us&edition=fundamental","pubTime":"2026-04-18 02:40","pubTimestamp":1776451218,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics’ ($KLRA) shares soared as high as 68% on Friday following their debut on Nasdaq, with the obesity treatment developer raising ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/kailera-stock-klra-rockets-60-after-ipo-as-it-chases-76b-obesity-opportunity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/kailera-stock-klra-rockets-60-after-ipo-as-it-chases-76b-obesity-opportunity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","IPOS","NQmain","SPCX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":89,"code":"91000000","status":"200"}]}}